Friday, 23 October 2026

Haematology

First CAR T Therapy for Relapsed or Refractory Adult ALL Now Reimbursed in Ireland

Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.

By Chantal Thurlby-Alexander Updated 2 min read
Tecartus CAR T therapy becomes first reimbursed option for relapsed or refractory adult ALL in Ireland.

1st December 2025, DUBLIN, IRELAND -– Gilead Sciences Ltd. and Kite, a Gilead company, today  announced that eligible patients in Ireland 26 years of age and above with relapsed or refractory B-cell  precursor acute lymphoblastic leukaemia (ALL) will now be able to access Tecartus® (brexucabtagene  autoleucel; brexu-cel) through the public health system. Brexucabtagene autoleucel is the first CAR T-cell  therapy to be reimbursed in Ireland for this patient population.  

Acute lymphoblastic leukaemia (ALL) is an uncommon acute haematological malignancy, representing  approximately 11% of all leukaemias in Ireland.1 While advances in chemotherapy and targeted  immunotherapies have improved overall survival, relapsed or refractory (r/r) adult ALL is associated with  “poor outcomes”.2 

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Related stories

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free